



# Booster Innovation Scheme

Annual Report 2026

---

**Booster Innovation Fund**

This Annual Report 2026 has been prepared for  
the period 1 April 2025 to 31 March 2026.

 **booster**

# Contents

<b>Section 1</b>	Details of the Scheme .....	3
<b>Section 2</b>	Description of the Scheme .....	3
<b>Section 3</b>	Information on composition of the Scheme .....	4
<b>Section 4</b>	Changes relating to the Scheme .....	5
<b>Section 5</b>	Financial condition and performance of the Scheme .....	7
<b>Section 6</b>	Fees .....	8
<b>Section 7</b>	Scheme property.....	9
<b>Section 8</b>	Changes to persons involved in the Scheme .....	13
<b>Section 9</b>	How to find further information .....	14
<b>Section 10</b>	Contact details and complaints .....	15

# 1. Details of the Scheme

---

<b>Name of the scheme:</b>	Booster Innovation Scheme ( <b>Scheme</b> )
<b>Manager:</b>	Booster Investment Management Limited ( <b>BIML</b> or <b>Manager</b> )
<b>Supervisor:</b>	Public Trust
<b>Product Disclosure Statement:</b>	The date and status of the latest Product Disclosure Statement for the Scheme is: <ul style="list-style-type: none"><li>• Booster Innovation Scheme – Booster Innovation Fund, dated 8 December 2025 – open for applications.</li></ul>
<b>Financial Statements and Auditor’s Report:</b>	The latest financial statements for the Scheme and its auditor report, covering the financial year 1 April 2025 to 31 March 2026 have been lodged on the scheme register and are available at <a href="http://www.disclose-register.companiesoffice.govt.nz">www.disclose-register.companiesoffice.govt.nz</a> or at <a href="http://www.booster.co.nz">www.booster.co.nz</a> .

## 2. Description of the Scheme

---

**Description of the Scheme:** The Booster Innovation Fund (the ‘**Fund**’) was established to invest in a portfolio of early-stage companies founded on intellectual property originated or developed in New Zealand that are selected on the basis that they have the potential to become commercially successful globally. The Fund was also listed on the NZX Main Board, code BIF, on 2 March 2022.

**Date on which the Scheme started:** The Scheme was established on 22 October 2020. The Scheme was initially offered as a wholesale scheme with its first transaction being on 24 August 2021. The Scheme was registered as a managed investment scheme on 10 November 2021 and became available to retail investors on 18 November 2021.

This Annual Report has been prepared for the year ended 31 March 2026, which covers the period 1 April 2025 to 31 March 2026 (the **Year**).

### 3. Information on composition of the Scheme

#### Units on issue

The number of units on issue in the Fund at the start and at the end of the Year was:

Fund	Units on issue at 1 April 2025 <sup>1</sup>	Units on issue at 31 March 2026
Booster Innovation Fund	14,416,518	16,330,729

<sup>1</sup>The opening units as at 1 April 2025 are the closing units as at 31 March 2026.

#### Substantial product holders

The Fund is listed on the NZX Main Board under NZX code BIF. Any unit holder that holds more than 5% of the units in the Fund considered to be a substantial product holder.

A list of the substantial product holders and their respective unit holding in the Fund, as at the end of the Year is as follows:

Substantial product holder	Unit holding	Percentage of holding
Booster KiwiSaver Scheme (through PT (Booster KiwiSaver) Nominees Limited)	9,102,726	55.7%
Asset Custodian Nominees Limited (ACNL) <sup>2</sup>	4,609,475	28.2%
<i>Included within ACNL: Units held as custodian for relevant interests of the Managing Director of the Manager's ultimate parent company, Booster Group Limited, Allan Yeo</i>	3,136,172	19.2%
<i>Of which the following units (being relevant interests of Allan Yeo) are held for Booster Financial Services Limited</i>	2,974,069	18.2%
Booster SuperScheme (through PT (Booster Superannuation) Nominees Limited)	1,380,858	8.9%

<sup>2</sup> ACNL holds units as a Custodian for underlying investors.

## 4. Changes relating to the Scheme

---

### Statement of Investment Policy and Objectives (SIPO)

No material changes were made to the SIPO of the Scheme's Fund during the Year. A copy of the Scheme's most recent SIPO is available at [www.booster.co.nz](http://www.booster.co.nz)

### Governing document

No changes were made to the Scheme's Trust Deed during the Year. A copy of the Scheme's Trust Deed is available at [www.booster.co.nz](http://www.booster.co.nz).

### Related party transactions

There were no material changes to the nature or scale of any related party transactions during the Year and all related party transactions that provided for a related party benefit were on arms' length terms.

The types of related party transactions that featured during the Year also featured in prior years, and included:

### Related parties acquiring units in the Scheme

- Related parties of the Scheme and other funds managed by the Manager may (and do) acquire, hold or dispose of units of the Fund and such transactions have continued during the Year.

### NZ Innovation Booster Limited Partnership

- The Scheme's Fund owns units in the NZ Innovation Booster Limited Partnership (NZIB). NZIB is a partnership between the Fund (via its custodian), BFSL, the parent company of the Manager, and Victoria Link Limited (Wellington UniVentures), Otago Innovation Limited (OIL) and Auckland Uni Services (AUS). Wellington UniVentures, OIL and AUS (together our 'investment partners') are wholly owned subsidiaries of Victoria University of Wellington, University of Otago and the University of Auckland respectively.

Due in part to BFSL being a shareholder of the general partner of NZIB, we consider NZIB to be a related party. As Wellington UniVentures, BFSL, OIL and AUS are shareholders of the general partner and are limited partners of NZIB, they could also be considered to be related parties. NZIB holds shares in the underlying businesses.

- During the Year, there were changes to the shareholders of NZIB's general partner and its limited partners:
  - On 8 December 2025, AUS joined NZIB as a new investment partner and became a shareholder of NZIB's general partner. This addition is expected to broaden BIF's investment pipeline and enhance access to early-stage investment opportunities across New Zealand's leading research institutions.
  - Following this change, the NZIB Limited Partnership (LP) Agreement was updated accordingly. In connection with this update, the ownership of NZIB's general partner was revised. BFSL and Wellington UniVentures each reduced their shareholding from 50% to 25%, while OIL and AUS each acquired a 25% shareholding in the general partner of NZIB.

### Capital Commitment

- BFSL committed an ongoing capital contribution into NZIB of up to \$2 million per year, on an average, for a minimum of 5 years when NZIB was formed in 2018, subject to the underlying investments meeting NZIB's investment criteria. Currently other Booster Managed Funds have agreed to take on 50% of that commitment. These commitments can be partly or wholly met by the Fund where it is determined to be in the best interests of the Fund and its investors.

## Purchase of interests in companies from Wellington UniVentures via NZIB

- As in previous years, during the Year the Fund acquired NZIB partnership units either from our investment partners or to support purchase by NZIB of an interest in businesses that were held outside of NZIB.
- Further information on the Fund and Related Party Benefits can be found in the Scheme's Product Disclosure Statement and Other Material Information document available at [www.booster.co.nz](http://www.booster.co.nz).

## Terms of the offer

Excluding matters noted below, there were no material changes made to the terms of the offer of the Scheme's Fund during the Year.

- **Climate reporting changes**
  - On 22 October 2025 the Government announced that Managed investment scheme (MIS) managers will be removed from the climate reporting regime and will no longer be required to produce annual climate statements. Following changes to regulatory requirements, the Manager has ceased preparing annual climate statements for the Fund with the statements for the year ended 31 March 2025 being the last.
- **Responsible Investment Policy Update**
  - During the Year, the Responsible Investment Policy was amended to clarify the approach to consideration of Environmental, Social and Governance (ESG) matters in investment decision making. ESG integration methodologies used for certain listed investments are not applied to unlisted investments (which this Fund invests in) as ESG comparisons can be harder to make.
- **Changes to the Fund's Investment Committee**
  - On 5 June 2025:
    - The Fund's Investment Committee ceased operating as a subcommittee of the Booster Investment Committee and fulfils the full Investment Committee role for the Fund, with reporting obligations to the Board of the Manager.
    - Daniela (Dana) McKenzie was appointed as a full member of the Fund's Investment Committee and ceased her role within the Advisors team.
- **Changes to the Fund's Advisor team**
  - On 5 June 2025, John Selby and Dana McKenzie ceased their roles from the Advisors team.
  - On 15 September 2025, Deborah (Deb) Shepard was appointed to the Advisors team.
  - On 20 November 2025, Craig Squire was appointed to the Advisors team.
- **During the Year, the Scheme's Product Disclosure Statement was updated to:**
  - reduce the minimum initial investment amount from \$1,000 to \$500;
  - note that valuation assessments for Fund interests held by NZIB would now follow the same approval process for directly held interests;
  - change the approved dispute resolution scheme provider to Financial Services Complaints Limited (effective 30 April 2025); and
  - other immaterial changes.

Refer to the Product Disclosure Statement for further information on the changes described above. A copy of the Scheme's current Product Disclosure Statement is available at [www.booster.co.nz](http://www.booster.co.nz)

## Valuation and pricing methodologies

No changes were made to the Scheme's Fund valuation and pricing methodologies during the Year that impact on the net asset value of the Fund or the value of investor's interests, except for the valuation approval process change for NZIB held interests noted above.

## 5. Financial condition and performance of the Scheme

The below information is a summary of the financial information for the Scheme for the year ended 31 March 2026 which provides a description of the Scheme's financial condition. The full financial statements are available at [www.disclose-register.companiesoffice.govt.nz](http://www.disclose-register.companiesoffice.govt.nz) or at [www.booster.co.nz](http://www.booster.co.nz).

The financial statements for the Fund are prepared under International Financial Reporting Standards, which differs to the approach applied for unit pricing purposes. There may be occasions where the financial statements are adjusted for information that becomes available post balance date relating to the year-end valuation in accordance with accounting standards. Unit pricing is adjusted as required to reflect new information received.

<b>Statement of Financial Performance of the Fund</b>	<b>For the year ended 31 March 2026 \$'000</b>
Investment income	1,764
Fees and expenses	(35)
<b>Net income before tax</b>	<b>1,729</b>

<b>Statement of Financial Position of the Fund</b>	<b>As at 31 March 2026 \$'000</b>
Cash	326
Investments held at fair value	24,470
Tax payable	(78)
Other payables	(35)
<b>Net Assets</b>	<b>24,683</b>

<b>Statement of Changes in net assets attributable to unitholders</b>	<b>For the year ended 31 March 2026 \$'000</b>
Net assets at the beginning of the period	20,363
Proceeds for units issued	3,074
Withdrawals	(347)
Net profit after tax	1,593
<b>Net Assets attributable to unitholders</b>	<b>24,683</b>

<b>Statement of Cash Flows</b>	<b>For the year ended 31 March 2026 \$'000</b>
Opening cash position	264
Net cash (outflows) from operating activities	(2,665)
Net cash inflows from financing activities	2,727
<b>Cash at end of the Year</b>	<b>326</b>

The below table shows the breakdown on investments held at fair value. Fair value adjustments refer to unrealised gains/losses for holdings during the period assessed in accordance with valuation methodologies for the Scheme.

<b>Investments held at fair value</b>	<b>For the year ended 31 March 2026 \$'000</b>
Opening balance (investments at 31 March 2025)	20,133
Acquisitions	2,585
Distributions	-
Fair value adjustments	1,756
Foreign exchange translation	(4)
<b>Investments at end of the Year</b>	<b>24,470</b>

## 6. Fees

Fees and expenses charged by the Fund through the unit price, but not including investor specific action fees, in respect of the Scheme for the Year are:

<b>Fee Type and Rate<sup>3</sup></b>	<b>Dollar Amount</b>	<b>Percentage of Scheme Property<sup>4</sup></b>
<b>Fees and Expenses Charged by the Manager or associated persons</b>		
Performance-based management fee	\$0	0.00%
<b>Fees and Expenses Charged by other persons</b>		
Capital raising expenses	nil	n/a
Other fund administration expenses	\$34,500	0.14%
Other fund administration expenses from underlying funds	\$20,488	0.08%

<sup>3</sup> The disclosed fees and expenses represent the amounts either disclosed or reflected in the financial statements of the Scheme's Fund over that period.

<sup>4</sup> The percentage is calculated based off the dollar amount divided by the average net asset value of the Scheme's Fund for the year to 31 March 2026.

Any new fees or changes to existing fees are subject to the Scheme Trust Deed. The Manager will consult and agree any fee change with the Supervisor and provide 1 month's notice of any increase in the fees or charges to all investors in the Fund. Expenses may vary from year to year.

## 7. Scheme property

As at 31 March 2026, the Fund held the following investments:

Company <sup>^</sup>	Company Stage	Description	Shareholding range	Investment made in year to 31/03/2026
Advemto Limited <sup>5</sup>	Seed	Developing ultrafast spectroscopy systems, that can reduce research analysis from months to days.	5 - 10%	No
Alimetry Limited <sup>5,6</sup>	Expansion	Sell non-invasive devices for aiding informed diagnostics for gastric disease.	0 - 5%	No
Allegro Energy Pty Limited <sup>5</sup>	Expansion	Developing high performance water-based electrolytes to provide a low cost, clean and green energy storage solution.	0 - 5%	No
Amaroq Therapeutics Pty Limited <sup>5</sup>	Seed	Developing a new class of therapeutics that target long non-coding RNA in cancer.	0 - 5%	No
Avasa Limited	Early stage	Developing a novel implantable medical device that aids in complex microvascular artery and vein reconstruction.	0 - 5%	Partial, additional 2% acquired
BioLumic Inc	Expansion	Improves crop yield and quality by treating seeds and seedlings with UV-light recipes.	0 - 5%	No
BioOra Limited	Expansion	Specialises in automating the CAR T-cell therapy manufacturing process to reduce costs and increase accessibility to cancer treatments.	0 - 5%	Partial, additional 1% acquired
Bontia Bio Limited <sup>5</sup>	Seed	Specialises in utilising proprietary synthetic biology technologies to create scalable production systems for commercially valuable compounds from nature.	10 - 15%	Partial, additional 5% acquired
B.Spkl Limited	Seed	Developing a unique manufacturing method and materials technology to produce a key component of hydrogen electrolyzers, aiming to facilitate viable green hydrogen production.	0 - 5%	No
Cadmus Animal Health	Seed	Developing an immunotherapeutic for the treatment of chronic periodontal disease in companion animals.	5 - 10%	Yes, in full
Calocurb Limited	Expansion	Selling a plant-based appetite suppressant, sourced from New Zealand hops, to assist people with chronic and debilitating obesity, a growing health epidemic internationally.	0 - 5%	No
Captivate Technology Limited	Seed	Developing a novel method of carbon capture, with potential to sequester greenhouse gas emissions across a range of industries.	0 - 5%	No
Chitogel Limited <sup>5</sup>	Expansion	Sell sinus dressings that helps to enhance wound healing and improve patient outcomes post-surgery.	0 - 5%	No

Ferronova Pty Limited <sup>5</sup>	Expansion	Developing surgical tracer systems that are designed to more accurately map cancer spread to lymph nodes.	0 - 5%	No
Hot Lime Labs Limited (trading as Aplenty)	Early stage	Selling carbon delivery systems to convert wood biomass into a more sustainable source of CO2 for use in horticulture.	0 - 5%	No
Indus Limited	Seed	Developing and marketing a unique investment platform to facilitate investment into India for people living abroad.	0 - 5%	Yes, in full
Inhibit Coatings Limited (trading as Argentix) <sup>5</sup>	Seed	Developing coatings to inhibit microbial contamination and outbreaks, targeting infection protection in the foot and ankle market.	5 - 10%	No
InsituGen Limited <sup>5</sup>	Seed	Developing testing solutions for measuring hormone activity in companion animals and for the detection of performance enhancing drug use in animals and humans.	5 - 10%	No
Kai's Education Limited	Early stage	Specialises in the development and sale of gamified and interactive learning tools with a focus on teaching STEM (science, technology, engineering, and mathematics) subjects to students.	0 - 5%	No
Komodo Holdings Limited	Early stage	Helping teachers and schools track the wellbeing of students using an interactive wellbeing platform.	0 - 5%	Partial, additional 1% acquired
Liquium Limited <sup>5</sup>	Seed	Seeking to revolutionise the ammonia production process making it cleaner, cheaper and scalable.	5 - 10%	No
MACSO Technologies Limited	Early stage	Selling cloud-based monitoring systems utilising human-like sensors and on-edge artificial intelligence to monitor changes in the built environment.	5 - 10%	No
Marama Labs Limited <sup>5</sup>	Early stage	Develops scientific hardware and data analytics solutions to help customers improve the quality of their production.	5 - 10%	No
Mars Bioimaging Limited	Expansion	Provides advanced spectral molecular imaging. Their technology combines the best of X-ray, CT, MRI, and PET scans to produce 3D, high-resolution, colour images for use in healthcare.	0 - 5%	Partial, additional 0.1% acquired
My Better Breathing Limited (trading as Good Air Nosebuds)	Seed	Developing and selling mechanical breathing technology to improve natural function and reduce nasal congestion.	0 - 5%	No
Nutrition From Water Inc	Early stage	Developing marine whey, a protein source produced from water and microalgae.	0 - 5%	No
Opo Bio Limited	Seed	Developing next generation bio-based ingredients for cosmetic and medical applications.	5 - 10%	No
Orbis Diagnostics Limited	Early stage	Developing point of care diagnostics for use in pharmacy and other settings.	0 - 5%	No

OrbViz Holdings Limited	Seed	A SaaS platform that transforms static reports and spreadsheets into interactive reports that stakeholders can easily access, explore and respond to.	0 - 5%	No
Scentian Bio Limited	Early stage	Developing and commercialising a unique sensing system, based on insect sensing receptors, that can define a digital reference for a taste and smell.	0 - 5%	Partial, additional 2% acquired
Sensor Holdings Limited (trading as StretchSense)	Expansion	Selling motion capture gloves that combine sensors and machine learning for hand and finger tracking in enterprise training, animation and gaming.	0 - 5%	No
Solros Therapeutics Limited <sup>5</sup>	Seed	Commercialising brain health focused therapies that take advantage of novel mechanisms of action.	5 - 10%	Partial, additional 5% acquired
Tectonus Limited	Expansion	Applies proprietary technology to multistorey buildings aiming to lower the cost of construction in seismic regions and provide owners and occupiers with a safer, more resilient building.	0 - 5%	Partial, additional 1% acquired
The Sustainable Care Company Limited (trading as Cleanery)	Expansion	Sell a range of eco-friendly cleaning and personal care products that aim to have a reduced environmental impact compared to existing solutions.	0 - 5%	No
Wave Propulsion Limited	Expansion	Merged entity of ZeroJet and Tectrax that provides eco-friendly electric jet propulsion and amphibious drive systems for innovative marine solutions.	0 - 5%	No
Wellumio Limited <sup>5</sup>	Early stage	Developing portable, magnetic resonance imaging (MRI) device to improve stroke treatment model.	0 - 5%	Partial, additional 1% acquired
Woolchemy NZ Limited	Early stage	Utilising wool to create intelligent eco-logical materials for personal care products.	0 - 5%	No
Wych Holdings Limited	Seed	Delivering secure, compliant, and scalable open data solutions through standardised APIs, reducing complexity, cost, and security risk.	0 - 5%	Yes, in full
XFrame Pty Limited <sup>5</sup>	Expansion	Selling recoverable, reusable building frames for sustainable construction.	5 - 10%	No
Zincovery Process Technologies Limited (trading as Zethos)	Early stage	Specialises in the recycling of critical minerals, having developed an alternative approach that can reduce carbon emissions.	0 - 5%	No


<sup>^</sup> Companies that have advised the Manager that they have been put into liquidation (and the Manager has valued at or near \$nil) are not included. Other companies with a \$nil are also not included.

<sup>5</sup> Investments are held indirectly via an interest in NZIB.


<sup>6</sup> Investment is held indirectly via NZIB which has an interest in the specific investees through an agreement with the Matū Karihi fund.

The following charts provide an analysis of the composition of the investment portfolio as at 31 March 2026.

### Portfolio value by business stage




### Portfolio value by sector



### Fund value by individual holding

This chart shows the relative size of each of the 40 active investments (excluding investments placed into liquidation and valued at nil) in which the Fund held an interest in as at 31 March 2026 (as a proportion of NAV). Commercial confidentiality obligations restrict the identification of each investment.



## 8. Changes to persons involved in the Scheme

---

### The Manager

BIML is the manager, administration manager and investment manager of the Scheme. This did not change during the Year.

### Changes to Directors of the Manager

During the Year the Manager had the following Board changes:

- On 1 December 2025, Allan Yeo stepped down from the Manager's Board of Directors, and Diana Papadopoulos has been appointed to the position of director, replacing her previous role as alternate director to Allan Yeo.

### Changes in Key Personnel of the Manager

- On 11 April 2025, Nic Craven stepped down as Chief Investment Officer of the Manager.
- On 9 May 2025, Nadine Brown was appointed as the Chief Customer Officer of the Manager, taking over the position recently vacated by Diana Papadopoulos following her appointment as Chief Executive Officer.
- On 11 September 2025, Simon O'Grady was appointed as Chief Investment Officer of the Manager.

### Changes to the group structure of the Manager

On 31 December 2025

- Two additional companies, Booster Group Limited (BGL) and Booster Financial Services Group Limited (BFSGL), were introduced into the group structure between the existing shareholders of Booster Financial Services Limited (BFSL), and BFSL. As a result, BGL became the parent company of BFSGL, and BFSGL became the parent company of BFSL. BFSL remains the immediate parent company of the Manager.

### The Supervisor

Public Trust is the Supervisor of the Scheme and this did not change during the Year.

During the Year, the Supervisor had the following Board changes:

- Karen Price was appointed as Chair of the Board of Public Trust effective 1 June 2025.
- William Peet was appointed as a Director of the Board of Public Trust effective 1 June 2025.

### Other Persons Involved

On 30 April 2025, the Manager changed its independent approved dispute resolution scheme provider from Financial Dispute Resolution Services (FDRS) to Financial Services Complaints Limited.

There were no changes to the Custodian (PT (Booster Investments) Nominees Limited), the Unit Registrar (MUFG Pension & Market Services (NZ) Limited), or the Auditor (Ernst & Young) during the Year.

## 9. How to find further information

---

Information relating to the Scheme is available on the offer register and scheme register at [www.disclose-register.companiesoffice.govt.nz](http://www.disclose-register.companiesoffice.govt.nz) by searching 'Booster Innovation Scheme' for the scheme register and 'Booster Innovation Fund' for the offer register:

- The **offer register** includes the Product Disclosure Statement, Other Material Information and material contracts for the Scheme.
- The **scheme register** includes the Trust Deed, the SIPO, the financial statements and the annual reports for the Scheme.

To request this annual report and other information about the Scheme and your investment (free of charge):

write to	Booster Investment Management Limited, PO Box 11872, Manners Street, Wellington 6142
email	<a href="mailto:investments@booster.co.nz">investments@booster.co.nz</a>
call	<b>0800 336 338</b> from 8.00am to 8.00pm (Monday to Friday)
visit	<a href="http://www.booster.co.nz">www.booster.co.nz</a>

## 10. Contact details and complaints

---

If you have any queries or complaints about the Scheme, you can contact the Manager (in the first instance), or the Supervisor, at the contact details below:

### Manager

#### Chief Operating Officer

Booster Investment Management Limited  
Level 19, Aon Centre, 1 Willis Street  
PO Box 11872, Manners Street  
Wellington 6142

Phone: **0800 336 338**

Email: [investments@booster.co.nz](mailto:investments@booster.co.nz)

### Supervisor

#### General Manager, Corporate Trustee Services

Public Trust  
Level 2, Public Trust Building,  
22-28 Willeston Street,  
Private Bag 5902  
Wellington 6140

Phone: **0800 371 471**

Email: [CTS.Enquiry@PublicTrust.co.nz](mailto:CTS.Enquiry@PublicTrust.co.nz)

If you have any queries on your listed securities holdings, you can contact the Unit Registrar on the contact details below:

### Unit Registrar

#### MUFG Pension & Market Services (NZ) Limited

Level 30, PwC Tower,  
15 Customs Street West  
PO Box 91976  
Auckland 1142

Phone: **09 375 5998**

Email: [nquiries.nz@cm.mpms.mufg.com](mailto:nquiries.nz@cm.mpms.mufg.com)

---

If your complaint can't be resolved by the Manager, the Supervisor or the Unit Registrar, you can refer to the following approved dispute resolution scheme run by Financial Services Complaints Limited (**FSCL**). FSCL will not charge you a fee to investigate or resolve your complaint.

You can contact FSCL at:

Level 4, 101 Lambton Quay  
PO Box 5967  
Wellington 6140

Phone: **0800 347 257**

Email: [complaints@fscl.org.nz](mailto:complaints@fscl.org.nz)

Website: [www.fscl.org.nz](http://www.fscl.org.nz)

Booster Investment Management Limited (**BIML**) is the issuer of the Booster Innovation Scheme. None of BIML, Public Trust, or any director, board member or nominee of any of those entities, or any other person guarantees the Scheme's performance, returns or repayment of capital. A copy of the Scheme's Product Disclosure Statement is available at [www.booster.co.nz](http://www.booster.co.nz).



### We're here to help.

To find out more about Booster Innovation Scheme, talk to your financial adviser, call us on **0800 336 338** or visit our website.

**[booster.co.nz](http://booster.co.nz)**

---

Booster Investment Management Limited  
PO Box 11872, Manners Street  
Wellington 6142, New Zealand

